Nonalcoholic steatohepatitis: Risk factors and diagnosis

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 5, 2010, Pages 623-635

  Adams, Leon A ^a   Feldstein, Ariel E ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

cirrhosis; cytokeratin 18; diabetes; insulin resistance; liver biopsy; nonalcoholic steatohepatitis; obesity

Indexed keywords

ADIPOCYTOKINE; ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; INTERLEUKIN 6; METHOTREXATE; PIOGLITAZONE; PREDNISOLONE; PROLINE DIPEPTIDASE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA;

AUTOPSY; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; COMORBIDITY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME BLOOD LEVEL; ETHNIC DIFFERENCE; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; PROGNOSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; BIOPSY; FATTY LIVER; HUMANS; LIVER; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 77958077003     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.56     Document Type: Review

References (123)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53(2), 372-384 (2010). Summarizes the proceedings of the 2009 EASL Special Conference on aminotransaminase/nonalcoholic steatohepatitis (NAFLD/NASH) and proposes expert opinions for different aspects of the clinical care of these patients.
2. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40, 1387-1395 (2004).
3. Das K, Mukherjee PS, Ghosh A et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51, 1593-1602 (2010).
4. Fan JG, Zhu G, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai China. J. Hepatol. 43, 508-513 (2005).
5. Nadalin S, Malago M, Valentin-Gamazo C et al. Preoperative donor liver biopsy for adult living donor liver transplantation: Risks and benefits. Liver Transpl. 11, 980-986 (2005). (Pubitemid 41122457)
6. Minervini MI, Ruppert K, Fontes P et al. Liver biopsy findings from healthy potential living liver donors: Reasons for disqualification, silent diseases and correlation with liver injury tests. J. Hepatol. 50, 501-510 (2009).
7. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 12, 1106-1110 (1990).
8. Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137, 532-540 (2009). Large long-term prospective study evaluating the changes in liver fibrosis and NASH features in severely obese patients after bariatric surgery.
9. Kallwitz ER, Guzman G, TenCate V et al. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am. J. Gastroenterol. 104, 64-69 (2009).
10. Carter-Kent C, Yerian LM, Brunt EM et al. Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study. Hepatology 50(4), 1113-1120 (2009). Muticenter study assessing liver histology in pediatric NAFLD.
11. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 40, 475-483 (2004).
12. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 37, 1202-1219 (2003).
13. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467-2474 (1999).
15. Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin. Gastroenterol. Hepatol. 7, 135-140 (2009).
16. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231 (2002).
17. de Ledinghen V, Ratziu V, Causse X et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J. Hepatol. 45, 592-599 (2006).
18. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic Fatty liver disease. Gastroenterology 128, 1898-1906 (2005).
19. Merriman RB, Ferrell LD, Patti MG et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44, 874-880 (2006).
20. Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes. Surg. 15, 497-501 (2005).
21. Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51, 595-602 (2010).
22. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129, 113-121 (2005). Largest community-based longitudinal study evaluating the natural history of NAFLD in the adult population.
23. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 22, 1714-1719 (1995).
24. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: Risk of chronic liver disease and death. Gut 53, 750-755 (2004).
25. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am. J. Gastroenterol. 97, 2058-2062 (2002).
26. Kuwabara H, Yoshii Y, Mori H et al. Nonalcoholic steatohepatitis-related cirrhosis with subacute liver failure: An autopsy case. Dig. Dis. Sci. 48, 1668-1670 (2003).
27. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873 (2006).
28. Targher G, Bertolini L, Rodella S et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabetes Care 30, 2119-2121 (2007). (Pubitemid 47219432)
29. Rafiq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7, 234-238 (2009).
30. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: A common cause of progressive chronic liver injury? J. Clin. Pathol. 55, 689-692 (2002).
31. Sanyal AJ, Banas C, Sargeant C et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682-689 (2006).
32. Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38, 420-427 (2003).
33. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch. Pathol. Lab. Med. 132, 1761-1766 (2008).
34. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972-1978 (2010). Largest study of patients with NASH-cirrhosis, demonstrating a greatly increased risk of liver cancer in these populations.
35. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am. J. Transplant. 9, 782-793 (2009).
36. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl. 15, 1814-1820 (2009).
37. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 16, 431-439 (2010).
38. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 15, 1843-1851 (2009).
39. Newsome PN. Recurrence of nonalcoholic fatty liver disease after liver transplantation: It is common, but does it affect outcome? Liver Transpl. 16, 420-422 (2010).
40. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645 (2009).
41. Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: A comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J. Hepatol. 49, 595-599 (2008).
42. Kadayifci A. Metabolic syndrome and liver transplantation. Panminerva. Med. 51, 205-213 (2009).
43. Perseghin G, Lattuada G, De Cobelli F et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47, 51-58 (2008).
44. Cali AM, Zern TL, Taksali SE et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: A perfect proatherogenic state. Diabetes Care 30, 3093-3098 (2007).
45. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 13, 1579-1584 (2007).
46. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. γ-glutamyltransferase is associated with incident vascular events independently of alcohol intake: Analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler. Thromb. Vasc. Biol. 27, 2729-2735 (2007).
47. Targher G, Bertolini L, Padovani R et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29, 1325-1330 (2006). (Pubitemid 44125930)
48. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 45, 600-606 (2006). Meta-analysis describing the liver histological features of over 1500 patients with severe obesity undergoing bariatric surgery.
49. Ibrahim MM. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes Rev. 11(1), 11-18 (2009).
50. van der Poorten D, Milner KL, Hui J et al. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology 48, 449-457 (2008).
51. Cheung O, Kapoor A, Puri P et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 46, 1091-1100 (2007).
52. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675-1685 (2010). Large multicenter randomized control study comparing placebo, vitamin E and pioglitazone, demonstrating that vitamin E was superior to placebo for NASH treatment.
53. Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132, 282-293 (2007).
54. Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am. J. Gastroenterol. 105, 336-344 (2010).
55. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40, 46-54 (2004).
56. Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 48, 792-798 (2008).
57. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am. J. Physiol. Endocrinol. Metab. 294, E15-E26 (2008).
58. Gade W, Schmit J, Collins M, Gade J. Beyond obesity: The diagnosis and pathophysiology of metabolic syndrome. Clin. Lab. Sci. 23, 51-61 (2010).
59. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917-923 (2003).
60. Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes. Surg. 17, 1457-1463 (2007).
61. Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 22, 1141-1145 (2005).
62. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with Type-2 diabetes mellitus. Liver Int. 29, 113-119 (2009).
63. Haukeland JW, Konopski Z, Linnestad P et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J. Gastroenterol. 40, 1469-1477 (2005).
64. Jacqueminet S, Lebray P, Morra R et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin. Gastroenterol. Hepatol. 6, 828-831 (2008).
65. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 42, 132-138 (2005). Longitudinal studies with serial liver biopsies demonstrating the rate of fibrosis progression in NASH patients and the lack of correlation with changes in serum aminotransferase levels.
66. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369-380 (2006).
67. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in Type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22, 756-761 (1999).
68. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 55, 1650-1660 (2006).
69. Milner KL, van der Poorten D, Xu A et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 49, 1926-1934 (2009).
70. Diab DL, Yerian L, Schauer P et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin. Gastroenterol. Hepatol. 6, 1249-1254 (2008).
71. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57, 1441-1447 (2008).
72. Sorrentino P, Tarantino G, Conca P et al. Silent nonalcoholic fatty liver disease - a clinical-histological study. J. Hepatol. 41, 751-757 (2004).
73. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37, 1286-1292 (2003). Provides clear evidence that the full spectrum of histological severity of NAFLD can be seen in patients with normal aminotransferases levels.
74. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 50, 1072-1078 (2009). Large multicenter study demonstrating the clinical utility of blood cytokeratin-18 fragment measurement for the diagnosis of NASH.
75. Kayadibi H, Gultepe M, Yasar B et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: A surrogate marker to distinguish steatohepatitis from simple steatosis. Dig. Dis. Sci. 54, 1764-1771 (2009).
76. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42, 650-656 (2005).
77. Feldstein AE, Canbay A, Angulo P et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 (2003).
78. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology 46, 582-589 (2007).
79. Younossi ZM, Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 18, 1430-1437 (2008).
80. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44, 27-33 (2006).
81. Malik R, Chang M, Bhaskar K et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 24, 564-568 (2009).
82. Yilmaz Y, Dolar E, Ulukaya E et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J. Gastroenterol. 13, 837-844 (2007).
83. Yilmaz Y. Systematic review: Caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment. Pharmacol. Ther. 30, 1103-1109 (2009).
84. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: Implications for treatment. Am. J. Gastroenterol. 103, 1036-1042 (2008).
85. Wong VW, Hui AY, Tsang SW et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4, 1154-1161 (2006).
86. Haukeland JW, Damas JK, Konopski Z et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44, 1167-1174 (2006).
87. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103, 1372-1379 (2008).
88. Li H, Fang Q, Gao F et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. DOI: 10.1016/j.jhep.2010.05.018 (2010) (Epub ahead of print).
89. Yilmaz Y, Eren F, Yonal O et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur. J. Clin. Invest. DOI: 10.1111/j.1365-2362.2010.02338.x (2010) (Epub ahead of print).
90. Dushay J, Chui PC, Gopalakrishnan GS et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139, 456-463 (2010).
91. Targher G, Bertolini L, Rodella S et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin. Endocrinol. (Oxf.) 64, 679-683 (2006).
92. Argentou M, Tiniakos DG, Karanikolas M et al. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes. Surg. 19, 1313-1323 (2009).
93. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 90, 3498-3504 (2005).
94. Aller R, de Luis DA, Fernandez L et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig. Dis. Sci. 53, 1088-1092 (2008).
95. Pagano C, Soardo G, Pilon C et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J. Clin. Endocrinol. Metab. 91, 1081-1086 (2006).
96. Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 27, 412-421 (2008).
97. Baranova A, Gowder SJ, Schlauch K et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes. Surg. 16, 1118-1125 (2006).
98. Charlton M, Angulo P, Chalasani N et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 47, 484-492 (2008).
99. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 50, 957-969 (2009).
100. Aller R, de Luis DA, Izaola O et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig. Dis. Sci. 54, 1772-1777 (2009).
101. Aktas B, Yilmaz Y, Eren F et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism DOI: 10.1016/j.metabol.2010.05.008 (2010) (Epub ahead of print).
102. Kukla M, Zwirska-Korczala K, Hartleb M et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 45, 235-242 (2010).
103. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr. Med. Chem. 13, 1971-1978 (2006).
104. Yilmaz Y, Ulukaya E, Gul OO et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin. Biochem. 42, 802-807 (2009).
105. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: Human data. Clin. Liver Dis. 11, 75-104 (2007).
106. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192 (2001).
107. Yesilova Z, Yaman H, Oktenli C et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100, 850-855 (2005).
108. Albano E, Mottaran E, Vidali M et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54, 987-993 (2005).
109. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497-1502 (2004).
110. Horoz M, Bolukbas C, Bolukbas FF et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol. 5, 35 (2005).
111. Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J. Clin. Gastroenterol. 40, 930-935 (2006).
112. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121, 91-100 (2001).
113. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 102, 399-408 (2007).
114. Campos GM, Bambha K, Vittinghoff E et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47, 1916-1923 (2008).
115. Ulitsky A, Ananthakrishnan AN, Komorowski R et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes. Surg. 20, 685-691 (2010).
116. Poynard T, Ratziu V, Charlotte F et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 6, 34 (2006).
117. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 26, 151-156 (2006).
118. Younossi ZM, Page S, Rafiq N et al. A biomarker panel for non-alcoholic Steatohepatitis (NASH) and NASH-related fibrosis. Obes. Surg. DOI: 10.1007/s11695-010-0204-1 (2010) (Epub ahead of print).
119. Yilmaz Y, Ulukaya E, Dolar E. A 'biomarker biopsy' for the diagnosis of NASH: Promises from CK-18 fragments. Obes. Surg. 18, 1507-1508 (2008).
120. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 48, 2086-2087 (2008).
121. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49, 306-317 (2009). Comprehensive review of the key clinical issues in NAFLD management.
122. Younossi ZM, Baranova A, Ziegler K et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42, 665-674 (2005). (Pubitemid 41233660)
123. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology 51, 373-375 (2010).